المؤلفون: Caballano-Infantes, Estefanía, Díaz, Irene, Hitos, Ana Belén, Cahuana, Gladys Margot, Martínez-Ruiz, Antonio, Soria-Juan, Bárbara, Rodríguez-Griñolo, Rosario, Hmadcha, Abdelkrim, Martín, Franz, Soria, Bernat, Tejedo, Juan R., Bedoya, Francisco Javier

المساهمون: Caballano-Infantes,E, Díaz,I, Hitos,AB, Hmadcha,A, Martín,F, Tejedo,JR, Bedoya,FJ Department of Regeneration and Cell Therapy, Andalusian Center for Molecular Biology and Regenerative Medicine (CABIMER), University of Pablo de Olavide-University of Seville-CSIC, Seville, Spain. Caballano-Infantes,E: Cahuana,GM, Bedoya,FJ Department of Molecular Biology and Biochemical Engineering, Universidad Pablo de Olavide, Seville, Spain. Díaz,I, Cahuana,GM, Soria,B, Bedoya,FJ Biomedical Research Network for Diabetes and Related Metabolic Diseases-CIBERDEM, Instituto de Salud Carlos III, Madrid, Spain. Martínez-Ruiz,A Unidad de Investigación, Hospital Universitario Santa Cristina, Instituto de Investigación Sanitaria Princesa (IIS-IP), Madrid, Spain. Soria-Juan,B Fundación Jiménez Díaz Health Research Institute, Madrid, Spain. Rodríguez-Griñolo,R Departamento de Economía, Métodos Cuantitativo e Historia Económica, Universidad Pablo de Olavide, Seville, Spain. Soria,B ISABIAL and Institute of Bioengineering, University Miguel Hernández de Elche, Alicante, Spain., E Caballano-Infantes was a doctoral FPU fellow from the Spanish government (FPU12/00184). This study was supported by grants from Consejería de Igualdad, Salud y Políticas Sociales, Junta de Andalucía (PI105/2010, TCMR06/009 and PI-0022) to FJ Bedoya and F Martin, from Consejería de Economía, Innovación, Ciencia y Empleo, Junta de Andalucía (CTS-7127/2011) to FJ. Bedoya, from ISCIII cofunded by Fondos FEDER (RED-TERCEL RD 16-011-0034) and from Fundación Andaluza de I + D (Grant Al-Andalus Biopharma 2019-2) to B. Soria and from Servicio Andaluz de Salud (SAS 11245) and Ministerio de Economía y Competitividad- Secretaría de Estado de Investigación Desarrollo e Innovación (IPT-2011-1615-900000) to JR Tejedo.

مصطلحات موضوعية: Pluripotency, Normoxia, Nitric oxide, Hypoxia, Metabolism, Hydroxylation, Mitochondria, Mitochondrial membranes, Proteasome inhibitor, Oxygen consumption, Glycolysis, Pluripotent stem cells, Óxido nítrico, Hipoxia, Metabolismo, Hidroxilación, Mitocondrias, Membranas mitocondriales, Inhibidores de proteasoma, Consumo de oxígeno, Glucólisis, Células madre pluripotentes, Medical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans, Medical Subject Headings::Chemicals and Drugs::Organic Chemicals::Amides::Benzamides::DEET, Medical Subject Headings::Phenomena and Processes::Metabolic Phenomena::Metabolism::Hydroxylation, Medical Subject Headings::Phenomena and Processes::Metabolic Phenomena::Metabolism::Energy Metabolism::Proton-Motive Force::Membrane Potential, Mitochondrial, Medical Subject Headings::Phenomena and Processes::Cell Physiological Phenomena::Cell Physiological Processes::Mitochondrial Turnover::Mitochondrial Dynamics, Medical Subject Headings::Chemicals and Drugs::Macromolecular Substances::Multiprotein Complexes::Multienzyme Complexes::Proteasome Endopeptidase Complex, Medical Subject Headings::Phenomena and Processes::Metabolic Phenomena::Oxygen Consumption

وصف الملف: application/pdf

العلاقة: https://www.mdpi.com/2076-3921/10/9/1408Test; Caballano-Infantes E, Díaz I, Hitos AB, Cahuana GM, Martínez-Ruiz A, Soria-Juan B, et al. Stemness of Human Pluripotent Cells: Hypoxia-Like Response Induced by Low Nitric Oxide. Antioxidants. 2021 Sep 2;10(9):1408; http://hdl.handle.net/10668/4473Test; PMC8472328

الإتاحة: https://doi.org/10.3390/antiox10091408Test
http://hdl.handle.net/10668/4473Test

المؤلفون: Ramos, Teresa Lopes, García-Guerrero, Estefanía, Caballero-Velázquez, Teresa, Rodríguez-Gil, Alfonso, Caracuel-García, Rocío, Nufer, Melanie, Robles-Frías, María José, Barbado, María Victoria, Pérez-Simón, José A.

المساهمون: Ramos,TL, García-Guerrero,E, Caballero-Velázquez,T, Rodríguez-Gil,A, Caracuel-García,R, Nufer,M, Robles-Frías,MJ, Barbado,MV, Pérez-Simón,JA Instituto de Biomedicina de Sevilla (IBIS/CSIC), CIBERONC, Universidad de Sevilla, Sevilla, Spain. Ramos,TL Division of Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, CA, USA. Caballero-Velázquez,T, Pérez-Simón,JA Department of Hematology, University Hospital Virgen del Rocio, Universidad de Sevilla, Sevilla, Spain., Takeda company (PCRS-2016-101751) partially supported the study, This work has been partially supported by the CIBERONC (CB16/12/00480), and TerCel 16/0011/0035. Spanish Association Against Cancer (AECC-POSTD18023LOPE) fellowship (TLR).

مصطلحات موضوعية: Bone marrow, Leukemia, Proteasome inhibitor, Ixazomib, Graft-versus-host disease, B cells, Médula ósea, Leucemia, Inhibidores de proteasoma, Enfermedad injerto contra huésped, Linfocitos B, Medical Subject Headings::Organisms::Eukaryota::Animals, Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Surgical Procedures, Operative::Transplantation::Tissue Transplantation::Bone Marrow Transplantation, Medical Subject Headings::Chemicals and Drugs::Inorganic Chemicals::Boron Compounds, Medical Subject Headings::Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Amino Acids::Glycine, Medical Subject Headings::Phenomena and Processes::Immune System Phenomena::Immune System Processes::Transplantation Immunology::Graft vs Host Reaction, Medical Subject Headings::Phenomena and Processes::Immune System Phenomena::Immunity, Medical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Rodentia::Muridae::Murinae::Mice, Medical Subject Headings::Diseases::Immune System Diseases::Graft vs Host Disease

وصف الملف: application/pdf; application/vnd.openxmlformats-officedocument.wordprocessingml.document

العلاقة: https://www.nature.com/articles/s41409-021-01452-1Test; Ramos TL, García-Guerrero E, Caballero-Velázquez T, Rodríguez-Gil A, Caracuel-García R, Nufer M, et al. Delayed administration of ixazomib modifies the immune response and prevents chronic graft-versus-host disease. Bone Marrow Transplant. 2021 Dec;56(12):3049-3058; http://hdl.handle.net/10668/4301Test; PMC8636253

الإتاحة: https://doi.org/10.1038/s41409-021-01452-1Test
http://hdl.handle.net/10668/4301Test

المؤلفون: Frías Fernández, Inés

المساهمون: Alarcón de la Lastra Romero, Catalina, Rosillo Ramírez, María de los Ángeles, Universidad de Sevilla. Departamento de Farmacología

مصطلحات موضوعية: Proteasoma, Sistema ubiquitin-proteasoma, Inhibidores de proteasoma, Cáncer, Enfermedades infecciosas

وصف الملف: application/pdf

العلاقة: https://idus.us.es/handle//11441/143775Test

الإتاحة: https://idus.us.es/handle//11441/143775Test

المؤلفون: Agnerys López Sacerio, Dumeivy García Sánchez

المصدر: Acta Médica del Centro, Vol 10, Iss 3, Pp 78-87 (2016)

مصطلحات موضوعية: inhibidores de proteasoma, bortezomib, mieloma múltiple, Medicine

وصف الملف: electronic resource

العلاقة: http://www.revactamedicacentro.sld.cu/index.php/amc/article/view/691Test; https://doaj.org/toc/2709-7927Test

الوصول الحر: https://doaj.org/article/e88764cf084c4e4baffa0abd49c5617aTest

المؤلفون: Teresa L. Ramos, Alfonso Rodríguez-Gil, José Antonio Pérez-Simón, Melanie Nufer, Teresa Caballero-Velázquez, Estefanía García-Guerrero, María Victoria Barbado, Rocío Caracuel-García, María José Robles-Frías

المساهمون: Universidad de Sevilla. Departamento de Medicina, Universidad de Sevilla. Departamento de Fisiología Médica y Biofísica, Universidad de Sevilla. Departamento de Citología e Histología Normal y Patológica, Takeda Pharmaceutical Company, Asociación Española Contra el Cáncer, Centro de Investigación Biomédica en Red Cáncer (España), [Ramos,TL, García-Guerrero,E, Caballero-Velázquez,T, Rodríguez-Gil,A, Caracuel-García,R, Nufer,M, Robles-Frías,MJ, Barbado,MV, Pérez-Simón,JA] Instituto de Biomedicina de Sevilla (IBIS/CSIC), CIBERONC, Universidad de Sevilla, Sevilla, Spain. [Ramos,TL] Division of Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, CA, USA. [Caballero-Velázquez,T, Pérez-Simón,JA] Department of Hematology, University Hospital Virgen del Rocio, Universidad de Sevilla, Sevilla, Spain., Takeda company (PCRS-2016-101751) partially supported the study, This work has been partially supported by the CIBERONC (CB16/12/00480), and TerCel 16/0011/0035. Spanish Association Against Cancer (AECC-POSTD18023LOPE) fellowship (TLR).

المصدر: Bone Marrow Transplantation
Digital.CSIC. Repositorio Institucional del CSIC
instname

مصطلحات موضوعية: Graft vs Host Disease, Phenomena and Processes::Immune System Phenomena::Immune System Processes::Transplantation Immunology::Graft vs Host Reaction [Medical Subject Headings], Disease, Graft-versus-host disease, Inhibidores de proteasoma, Ixazomib, Mice, chemistry.chemical_compound, immune system diseases, Organisms::Eukaryota::Animals [Medical Subject Headings], Proteasome inhibitor, Bone Marrow Transplantation, Leukemia, Effector, Médula ósea, Hematology, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Surgical Procedures, Operative::Transplantation::Tissue Transplantation::Bone Marrow Transplantation [Medical Subject Headings], Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Amino Acids::Glycine [Medical Subject Headings], surgical procedures, operative, medicine.anatomical_structure, Linfocitos B, medicine.drug, Boron Compounds, Bone marrow transplantation, Glycine, Graft vs Leukemia Effect, Enfermedad injerto contra huésped, Article, Immune system, medicine, Animals, Bone marrow, Leucemia, B cells, Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Rodentia::Muridae::Murinae::Mice [Medical Subject Headings], Transplantation, business.industry, Immunity, Phenomena and Processes::Immune System Phenomena::Immunity [Medical Subject Headings], Translational research, medicine.disease, Diseases::Immune System Diseases::Graft vs Host Disease [Medical Subject Headings], chemistry, Immunology, business, Chemicals and Drugs::Inorganic Chemicals::Boron Compounds [Medical Subject Headings]

وصف الملف: application/pdf; application/vnd.openxmlformats-officedocument.wordprocessingml.document

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::227fcab3b1ab31aee8f3643f5967ee34Test
https://doi.org/10.1038/s41409-021-01452-1Test

المؤلفون: Frías Fernández, Inés

المساهمون: Alarcón de la Lastra Romero, Catalina, Rosillo Ramírez, María de los Ángeles, Universidad de Sevilla. Departamento de Farmacología

مصطلحات موضوعية: Sistema ubiquitin-proteasoma, Enfermedades infecciosas, Cáncer, Proteasoma, Inhibidores de proteasoma

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=od______3272::ba85a66dba1c0b9ef08c4d207b02c42cTest

المؤلفون: López Sacerio, Agnerys, García Sánchez, Dumeivy

المصدر: Acta Médica del Centro; Vol. 10, No. 3 (2016): julio-septiembre; 78-87 ; 2709-7927

مصطلحات موضوعية: proteasome inhibitors, bortezomib, multiple myeloma, inhibidores de proteasoma, mieloma múltiple

وصف الملف: application/pdf

العلاقة: https://revactamedicacentro.sld.cu/index.php/amc/article/view/691/784Test; Moreau P, Richardson PG, Cavo M, Orlowski RZ, San Miguel JF, Palumbo A, et al. Proteasome inhibitors in multiple myeloma: 10 years later. Blood. 2012 Aug 2;120(5): 947–59. doi:10.1182/blood-2012-04-403733. PMCID: PMC4123429; He J, Yang L, Han X, Zheng G, Zheng W. The Choice of Regimens Based on Bortezomib for Patients with Newly Diagnosed Multiple Myeloma. PLoS ONE. 2014;9(6):e99174. doi:10.1371/journal.pone.0099174; Manni S, Brancalion A, Mandato E, Tubi LQ, Colpo A. Protein Kinase CK2 Inhibition Down Modulates the NF-kB and STAT3 Survival Pathways, Enhances the Cellular Proteotoxic Stress and Synergistically Boosts the Cytotoxic Effect of Bortezomib on Multiple Myeloma and Mantle Cell Lymphoma Cells. PLoS ONE. 2013;8(9): e75280. doi:10.1371/journal.pone.0075280; Kouroukis TC, Baldassamorre FC, Haynes AE, Imrie K, Reece DE, Cheung MC. Bortezomib in MM: systematic review and clinical considerations. Curr Oncol. 2014 Aug;21(4):573-603.; Barosi G, Merlini G, Billio A. SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma. Ann Hematol. 2012;91:875–88. doi:10.1007/s00277-012-1445-y.; Hjorth M, Hjertner O, Knudsen LM. On behalf of the Nordic Myeloma Study Group (nmsg). Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study. Eur J Haematol. 2012 Jun;88(6):485-96. doi:10.1111/j.1600-0609.2012.01775.x.; Kumar S, Flinn I, Richardson PG. Randomized, multicenter, phase2 study (evolution) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood. 2012 May 10;119(19):4375-82.; Sharma M, Khan H, Thall PF. A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid. Cancer. 2012;118(9):2507–15.; Garderet L, Iacobelli S, Moreau P. Superiority of the triple combination of bortezomib–thalidomide–dexamethasone over the dual combination of thalidomide–dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: The mmvar/ifm2005-04 randomized phase iii trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2012;30(20):2475–82.; Sonneveld P, Schmidt–Wolf IG, Van der Holt B. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase iii hovon-65/gmmg-hd 4trial. J Clin Oncol. 2012;30:2946–55.; Cavo M, Pantani L, Petrucci MT. Bortezomib–thalidomide–dexamethasone is superior to thalidomide–dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood. 2012;120:9–11.; Neben K, Lokhorst HM, Jauch A. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion17p. Blood. 2012;119(4):940–8.; Kaura S, Dranitsaris G. Number needed to treat (nnt) as a measure of drug benefit: lenalidomide versus bortezomib for treatment of relapsed/refractory multiple myeloma (mm). J Clin Oncol [Internet]. 2012 [citado 4 Abr 2014];30: e18562. Disponible en: http://meetinglibrary.asco.org/content/96962-114Test; Rosinol L, Cibeira MT, Mateos MV. A phase3 pethema/gem randomised trial of posttransplant maintenance in multiple myeloma: superiority of bortezomib. Bone Marrow Transplant. 2013;47:S2.; Zinzani PL. Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial. J Hematol Oncol. 2012;5:67. Published online 2012 Oct 22. doi:10.1186/1756-8722-5-67.; Mellqvist UH, Gimsing P, Hjertner O, Lenhoff S, Laane E, Remes K, et al. Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial. Blood. 2013 Jun 6;121(23):4647-54. doi:10.1182/blood-2012-11-464503. Epub 2013 Apr 24.; Leleu X, Fouquet G, Hebraud B, Roussel M, Caillot D, Chretien ML, et al. Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma. Leukemia. 2013 Nov;27(11):2242-4. doi:10.1038/leu.2013.101. Epub 2013 Apr 5.; Kamimura T, Miyamoto T, Yokota N, Takashima S, Chong Y, Ito Y, et al. Higher incidence of injection site reactions after subcutaneous bortezomib administration on the thigh compared with the abdomen. Eur J Haematol. 2013 Feb;90(2):157-61. doi:10.1111/ejh.12055. Epub 2013 Jan 9.; Takashima S, Miyamoto T, Kadawoki M, Ito Y, Aoki T,Takase T, et al. Combination of bortezomib, thalidomide, and dexamethasone (VTD) as a consolidation therapy after autologous stem cell transplantation for symptomatic multiple myeloma in Japanese patients. Int J Hematol. 2014 Aug;100(2):159-64. doi:10.1007/s12185-014-1611-1.; Kunami N, Katsuya H, Nogami R. Promise of combining a Bcl-2 family inhibitor with bortezomib or SAHA for adult T-cell leukemia/lymphoma. Anticancer Res. 2014 Oct;34(10):5287–94.; Holkova B, Kmieciak M, Perkins EB. Phase I trial of bortezomib (PS-341; NSC 681239) and ‘‘nonhybrid’’ (Bolus) infusion schedule of alvocidib (Flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms. Clin Cancer Res. 2014 Nov 15;20(22):5652–62.; Kumar SK, Berdeja JD, Niesvizky R. A phase 1/2 study of weekly MLN9708, an investigational oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma (MM). Blood. 2012;119:4375-82.; Niesvizky R, Martin TG, Bensinger WI. Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Clin Cancer Res. 2013 Apr 15;19(8):2248-56. doi:10.1158/1078-0432.; Hurchla MA, García-Gómez A, Hornick MC, Ocio EM, Li A, Blanco JF et al. The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects. Leucemia. 2013 Feb;27(2):430-40. doi:10.1038/leu.2012.183.; Ribrag V, Tilly H, Casasnovas O. Efficacy and toxicity of two schedules of bortezomib in patients withrecurrent or refractory follicular lymphoma: a randomised phase II trial from the Groupe d’Etude des Lymphomes de l’Adulte (GELA). Eur J Cancer. 2013 Mar;49(4):904-10. doi:10.1016/j.ejca.2012.11.015. Epub 2012 Dec.; Furtado M, Johnson R, Kruger A. Addition of bortezomib to standard dose chop chemotherapy improves response and survival in relapsed mantle cell lymphoma. Br J Haematol. 2015 Jan;168(1):55-62. doi:10.1111/bjh.13101. Epub 2014 Aug 22.; Gerrie AS, Mikhael JR, Cheng L, Jiang H, Kukreti V, Panzarella T, et al. D(T)PACE as salvage therapy for aggressive or refractory multiple myeloma. Br J Haematol. 2013 Jun;161(6):802-10. doi:10.1111/bjh.12325. Epub 2013 Apr 18.; Bose P, Batalo MS, Holkova B. Bortezomib for the treatment of non- Hodgkin’s lymphoma. Expert Opin Pharmacother. 2014 Nov;15(16):2443-59. doi:10.1517/14656566.2014.965142. Epub 2014 Sep 29.; Goda AE, Erikson RL, Sakai T. Preclinical evaluation of bortezomib/dipyridamole novel combination as a potential therapeutic modality for hematologic malignancies. Mol Oncol. 2015 Jan;9(1):309-22. doi:10.1016/j.molonc.2014.08.010. Epub 2014 Sep 6.; Craig M, Hanna WT, Cabanillas F. Phase II study of bortezomib in combination with rituximab, cyclophosphamide and prednisone with or without doxorubicin followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma. Br J Haematol. 2014;166(6):920–8. doi:10.1111/bjh.12991.; Yun H, Zhang HL, Wag HQ. Rituximab and Bortezomib(RB): a new effective regimen for refractory or relapsed indolent lymphoma. Med Oncol. 2015;32:353. doi:10.1007/s12032-014-0353-5.; https://revactamedicacentro.sld.cu/index.php/amc/article/view/691Test

الإتاحة: https://doi.org/10.1182/blood-2012-04-403733Test
https://doi.org/10.1371/journal.pone.0099174Test
https://doi.org/10.1371/journal.pone.0075280Test
https://doi.org/10.1007/s00277-012-1445-yTest
https://doi.org/10.1111/j.1600-0609.2012.01775.xTest
https://doi.org/10.1186/1756-8722-5-67Test
https://doi.org/10.1182/blood-2012-11-464503Test
https://doi.org/10.1038/leu.2013.101Test
https://doi.org/10.1111/ejh.12055Test
https://doi.org/10.1007/s12185-014-1611-1Test

المؤلفون: Abdelkrim Hmadcha, Irene Díaz, Gladys M. Cahuana, Bernat Soria, Ana B. Hitos, Franz Martín, Francisco J. Bedoya, Antonio Martínez-Ruiz, Bárbara Soria-Juan, Juan R. Tejedo, Rosario Rodríguez-Griñolo, Estefanía Caballano-Infantes

المساهمون: [Caballano-Infantes,E, Díaz,I, Hitos,AB, Hmadcha,A, Martín,F, Tejedo,JR, Bedoya,FJ] Department of Regeneration and Cell Therapy, Andalusian Center for Molecular Biology and Regenerative Medicine (CABIMER), University of Pablo de Olavide-University of Seville-CSIC, Seville, Spain. [Caballano-Infantes,E: Cahuana,GM, Bedoya,FJ] Department of Molecular Biology and Biochemical Engineering, Universidad Pablo de Olavide, Seville, Spain. [Díaz,I, Cahuana,GM, Soria,B, Bedoya,FJ] Biomedical Research Network for Diabetes and Related Metabolic Diseases-CIBERDEM, Instituto de Salud Carlos III, Madrid, Spain. [Martínez-Ruiz,A] Unidad de Investigación, Hospital Universitario Santa Cristina, Instituto de Investigación Sanitaria Princesa (IIS-IP), Madrid, Spain. [Soria-Juan,B] Fundación Jiménez Díaz Health Research Institute, Madrid, Spain. [Rodríguez-Griñolo,R] Departamento de Economía, Métodos Cuantitativo e Historia Económica, Universidad Pablo de Olavide, Seville, Spain. [Soria,B] ISABIAL and Institute of Bioengineering, University Miguel Hernández de Elche, Alicante, Spain., E Caballano-Infantes was a doctoral FPU fellow from the Spanish government (FPU12/00184). This study was supported by grants from Consejería de Igualdad, Salud y Políticas Sociales, Junta de Andalucía (PI105/2010, TCMR06/009 and PI-0022) to FJ Bedoya and F Martin, from Consejería de Economía, Innovación, Ciencia y Empleo, Junta de Andalucía (CTS-7127/2011) to FJ. Bedoya, from ISCIII cofunded by Fondos FEDER (RED-TERCEL RD 16-011-0034) and from Fundación Andaluza de I + D (Grant Al-Andalus Biopharma 2019-2) to B. Soria and from Servicio Andaluz de Salud (SAS 11245) and Ministerio de Economía y Competitividad- Secretaría de Estado de Investigación Desarrollo e Innovación (IPT-2011-1615-900000) to JR Tejedo.

المصدر: Antioxidants
Volume 10
Issue 9
Antioxidants, Vol 10, Iss 1408, p 1408 (2021)

مصطلحات موضوعية: Physiology, Clinical Biochemistry, Membranas mitocondriales, Biochemistry, Inhibidores de proteasoma, Hydroxylation, Células madre pluripotentes, Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], chemistry.chemical_compound, Chemicals and Drugs::Organic Chemicals::Amides::Benzamides::DEET [Medical Subject Headings], Chemicals and Drugs::Macromolecular Substances::Multiprotein Complexes::Multienzyme Complexes::Proteasome Endopeptidase Complex [Medical Subject Headings], Glycolysis, Proteasome inhibitor, Hipoxia, Consumo de oxígeno, Induced pluripotent stem cell, Hypoxia, Mitocondrias, Metabolismo, Phenomena and Processes::Metabolic Phenomena::Metabolome [Medical Subject Headings], Chemistry, Phenomena and Processes::Metabolic Phenomena::Metabolism::Hydroxylation [Medical Subject Headings], Chemicals and Drugs::Inorganic Chemicals::Free Radicals::Nitric Oxide [Medical Subject Headings], Cell biology, Mitochondria, mitochondrial fusion, Phenomena and Processes::Metabolic Phenomena::Metabolism::Energy Metabolism::Proton-Motive Force::Membrane Potential, Mitochondrial [Medical Subject Headings], Phenomena and Processes::Cell Physiological Phenomena::Cell Physiological Processes::Mitochondrial Turnover::Mitochondrial Dynamics [Medical Subject Headings], Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::DNA-Binding Proteins::Basic Helix-Loop-Helix Transcription Factors [Medical Subject Headings], medicine.symptom, Homeobox protein NANOG, Pluripotency, Phenomena and Processes::Chemical Phenomena::Biochemical Phenomena::Biochemical Processes::Carbohydrate Metabolism::Glycolysis [Medical Subject Headings], normoxia, Oxygen consumption, RM1-950, Anatomy::Cells::Stem Cells::Pluripotent Stem Cells [Medical Subject Headings], Article, Nitric oxide, Downregulation and upregulation, Pluripotent stem cells, nitric oxide, Phenomena and Processes::Metabolic Phenomena::Oxygen Consumption [Medical Subject Headings], medicine, Phenomena and Processes::Metabolic Phenomena::Metabolism [Medical Subject Headings], Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Enzyme Inhibitors::Protease Inhibitors::Proteasome Inhibitors [Medical Subject Headings], Molecular Biology, Diseases::Pathological Conditions, Signs and Symptoms::Signs and Symptoms::Signs and Symptoms, Respiratory::Anoxia [Medical Subject Headings], Mitochondrial membranes, hypoxia, Hidroxilación, Cell Biology, Hypoxia (medical), pluripotency, Glucólisis, Metabolism, Therapeutics. Pharmacology, Normoxia, metabolism, Óxido nítrico

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::564747978055438567a3bbfbe193457aTest
https://hdl.handle.net/10668/4473Test

المؤلفون: Ruano, Diego

المساهمون: [Ruano,D] Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/Consejo Superior de Investigaciones Científicas/Universidad de Sevilla, Sevilla, Spain, [Ruano,D] Departamento de Bioquímica y Biología Molecular, Facultad de Farmacia, Universidad de Sevilla, Sevilla, Spain., This work was supported by grants from the Junta de Andalucía to the research group CTS257-Aging and Neurodegeneration.

مصطلحات موضوعية: Diseases::Nutritional and Metabolic Diseases::Metabolic Diseases::Proteostasis Deficiencies [Medical Subject Headings], Aging, Molecular chaperones, Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Molecular Chaperones [Medical Subject Headings], Envejecimiento, Autofagia, Diseases::Nervous System Diseases::Neurodegenerative Diseases::Motor Neuron Disease::Amyotrophic Lateral Sclerosis [Medical Subject Headings], Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Risk::Risk Factors [Medical Subject Headings], Inhibidores de proteasoma, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Vital Statistics::Morbidity::Incidence [Medical Subject Headings], Phenomena and Processes::Physiological Phenomena::Physiological Processes::Growth and Development::Aging [Medical Subject Headings], Autophagy, Chaperonas moleculares, Persons::Persons::Age Groups::Adult::Aged [Medical Subject Headings], Inflammation, Proteasome, Inflamación, Senescencia celular, Psychiatry and Psychology::Psychological Phenomena and Processes::Mental Processes::Cognition::Comprehension [Medical Subject Headings], Diseases::Endocrine System Diseases::Diabetes Mellitus [Medical Subject Headings], Diseases::Neoplasms [Medical Subject Headings], Cell stress and aging, Amyotrophic lateral sclerosis, Proteostasis, Diseases::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Inflammation [Medical Subject Headings], Esclerosis amiotrófica lateral

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=od______2636::ddec946c0d836433661858c47a9a9eb4Test
https://hdl.handle.net/10668/4244Test

المؤلفون: Vallejo, R.

المصدر: Revista Hematología, ISSN 2250-8309, Vol. 23, Nº. 3, 2019 (Ejemplar dedicado a: SEPTIEMBRE - DICIEMBRE 2019), pags. 16-24

مصطلحات موضوعية: mieloma múltiple, inhibidores de proteasoma, bortezomib, carfilzomib, efectos adversos, multiple myeloma, proteasome inhibitors, adverse effects

وصف الملف: application/pdf

العلاقة: https://dialnet.unirioja.es/servlet/oaiart?codigo=8778375Test; (Revista) ISSN 0329-0379; (Revista) ISSN 2250-8309

الإتاحة: https://dialnet.unirioja.es/servlet/oaiart?codigo=8778375Test